An international group of researchers has set up a brain-machine interface between cultured nerve cells and electronic chips linked over the internet, which could lead to the development of AI implants for treating neurological disorders.

As described in a study published in Nature Scientific Reports, the team set up a system where cultured rat nerve cells in Italy could send real-time electrical signals to artificial neurons circuits that behave like nerve cells in Switzerland. The online signals were passed via electronic synapses or memristors in the UK. The signals could also go the other way, sending communications from the artificial nerve cells to the biological nerve cells.

Technology linking the nervous system with machines, called neural interfacing, is an established field, including technology such as cochlear implants treating hearing loss. In the last few decades, however, scientists have made technological advances that let machines use artificial neural networks and integrate better with real brains. This could lead to implantable AI computing chips that treat complex neurological problems like Parkinsons disease.

One key challenge to developing brain-machine interfaces is that lots of time, effort and money are needed to get experts and specialist equipment in one place to link up. This is what the researchers, based in the UK, Italy, Germany, and Switzerland, wanted to combat by connecting nerve cells with machines via the internet.

The virtual lab connecting Southampton, UK; Zurich, Switzerland; and Padova, Italy.

To achieve the same outcome, scientists would have to be co-located, spending significant time in a place and resources for physically linking the capabilities, said Themis Prodromakis, Professor of Nanotechnology at the University of Southampton, and lead author of the study.

There are several academic groups and companies also developing brain-machine interfaces, such as the US firm Blackrock Microsystems and the Dublin-based Medtronic. However, Prodromakis told me that this is the first time anyone has combined biological nerve cells, artificial nerve cells, and memristors into one system across the internet.

It sets the basis for a novel scenario that was never encountered during natural evolution, where biological and artificial neurons are linked together and communicate across global networks; laying the foundations for the internet of neuro-electronics, Prodromakis stated.

This study could pave the way for advances in neurological treatments. For example, it could lead to implanted AI chips that can help patients to control blood pressure, or prevent bladder problems caused by neurological conditions.

In another potential application, AI implants could treat the symptoms of Parkinsons disease patients. Unlike deep brain stimulation a neurostimulation technique currently used for some patients with Parkinsons disease this tech could learn and replace the function of damaged brain tissue.

Image from Shutterstock and the University of Southampton

Read the rest here:
Scientists Connect Brain Cells to Machines Over the... - Labiotech.eu

Bill Maher said that Democrats have to stop talking about playing as dirty as the Republicans and start doing it and hes gave them a head start by making a campaign ad for the 2020 presidential election that targets Trumps brain.

Ever since Democrats lost the 2016 election theres been a backlash to the when they go low, we go high approach, Maher said on Fridays Real Time. But they never say what exactly it is we should do, just, We gotta fight dirty. OK. But how?

After recommending Democrats enlist some reptilian scumbags of our own to match the efforts of Republican dirty tricksters on their payroll like Roger Stone, Karl Rove and Rudy Giuliani, Maher said he then suggested focusing on Trumps mental state.

Also Read: Bill Maher Also Feels Pretty Hopeless After Today's Senate Vote on Impeachment Witnesses

Trump is a neurological mess, but the Democrats are too scared to make an issue of it when actually it would cut together really well as a campaign ad, the comedian said, cuing the video.

The ad showed the president mumbling and stumbling over his words, recalling how those whove known Trump in the past have said hes not the same person he was and another saying he may be having small strokes. It ends with footage of the POTUS boarding Air Force One with toilet paper stuck on his shoe.

Also Read: Senate Republicans Vote Down Additional Witnesses in Trump Impeachment Trial

No one wishes ill health on the president, but a country needs a leader to be there a leader who is ALL there, the ad concluded.

Maher added, Make that go viral, would ya, because Democrats should really be running that for real.

You can catch the faux ad above followed by a Real Time creation of a deepfake of the infamous (and completely unsubstantiated) pee tape.

There's just over a year to go until the 2020 presidential election, but the competition to potentially replace Donald Trump in the White House is already stiff.

There's a lot to keep track of, but we're here to help. Here's TheWrap's list of everyone who is running for president so far and who has dropped out.

Joe Biden Democratic Party

Entered Race: April 25, 2019

The former Obama VP was a late entry to the race, formally declaring his run for the presidency on April 25. But he's long been a presumed frontrunner, leading many early polls. This is his third presidential run, and for months he's been telling anyone who'll listen that he'd be the most qualified candidate for the job. He's also already been under scrutiny over criticism about his behavior with women, prompting him to post a video promising he'd be "more mindful and respectful" of a woman's "personal space."

Biden has also been prone to embarrassing slips of the tongue, among them placing the assassinations of RFK and MLK in "the late '70s," mistaking his campaign's text number for a website, waxing nostalgic about his friendships with Senate segregationists, and saying "poor kids are just as bright and just as talented as white kids."

Elizabeth Warren Democratic Party

Entered Race: Feb. 9, 2019

The Massachusetts Senator formally announced her candidacy on Feb. 9 at a rally in her home state, and shortly after followed up with a tweet that read: "I believe in an America of opportunity. My daddy ended up as a janitor, but his little girl got the chance to be a public school teacher, a college professor, a United States Senator and a candidate for President of the United States. #Warren2020."

Bernie Sanders Democratic Party

Entered Race: Feb. 19, 2019

Bernie Sanders, the runner-up in the 2016 contest for the Democratic nomination, has recorded a campaign video in which he says he is running for president in 2020, according to a report in Politico.

Pete Buttigieg Democratic Party

Entered Race: April 14, 2019

The 37-year-old mayor of South Bend, Indiana would becomethe first openly gay presidential nominee from a major political party. Buttigieg's platform includes a plan to further empower Black America and economic reform.

Tulsi Gabbard Democratic Party

Entered Race: Jan. 11, 2019

Gabbard, a U.S. Representative for Hawaii's 2nd congressional district, endorsed Bernie Sanders in 2016, but in 2020 she's all-in on herself. Gabbard is running on immigration and criminal justice reform.

Andrew Yang Democratic Party

Entered Race: Nov. 6, 2017

The entrepreneur and son of immigrant parents from Taiwan became a contender a year ago, tellingThe New York Timesthat he will advocate for a universal basic income.

John Delaney Democratic Party

Entered Race: July 28, 2017

TheU.S. Representative for Maryland's 6th district declaredback in July 2017. He says he'll "end reckless trade wars and expand trade," "create a universal health care system" and "launch a national AI strategy."

Amy Klobuchar Democratic Party

Entered Race: Feb. 10, 2019

The Minnesota Democrat, first elected to the U.S. Senate in 2006, announced her bid on Feb. 10, 2019, saying that she wanted to work for "everyone who wanted their work recognized." Klobuchar's key issues she wants to tackle if elected president include revising voting rights protections and prioritizing cybersecurity.

Michael Bennet Democratic Party

Entered Race: May 2, 2019

The Colorado senator has been a vocal supporter on advancing the field of artificial intelligence and expanding the Child Tax Credit. He didn't qualify for the fourth Democratic debate but he's vowed to keep running.

Wayne Messam Democratic Candidate

Entered Race: March 28, 2019

The mayor of Miramar, Florida, a city near Miami, is a first-generation American who has called for end the filibuster and erasing student debt. He only raised $5 -- five -- during the quarter that ended Sep. 30, but he's still in the race.

Tom Steyer Democratic Party

Entered Race: July 9, 2019

The billionaire and climate change activist entered the race in July, saying in a video "if you think that there's something absolutely critical, try as hard as you can and let the chips fall where they may. And that's exactly what I'm doing. My name's Tom Steyer, and I'm running for president."

Joe Sestak Democratic Party

Entered Race: June 23, 2019

The former Pennsylvania Congressman has a plan for America that includes investing in American manufacturing and strengthening antitrust laws.

Deval Patrick - Democratic Party

Entered Race: Nov. 14, 2019

The former governor of Massachusetts acknowledged the challenge of jumping into the Democratic primary so late in the game. But in his announcement he took a veiled swipe at other candidates, saying the party was torn between "nostalgia" and "our big idea or no way.

Michael Bloomberg - Democratic Party

Entered Race: Nov. 24, 2019

The former mayor of New York is the second billionaire to enter the crowded Democratic field with just one year until the election. Bloomberg plans to fund his own campaign and is reportedly spending $30 million in TV ads to launch his campaign.

Bill Weld Republican Party

Entered Race: April 15, 2019

Weld is a former Governor of Massachusetts who has been on the record about his displeasure of Trump, specifically Trump's desire to be more of a "king than a president."

Joe Walsh Republican Party

Entered Race: Aug. 25, 2019

The former congressman from Illinois turned conservative talk show host announced in August 2019 that he would enter the GOP primaries to challenge President Trump. "I'm running because he's unfit; somebody needs to step up and there needs to be an alternative. The country is sick of this guy's tantrum -- he's a child," he told ABC News.

Cory Booker Democratic Party

Entered Race: Feb. 1, 2019

Dropped Out: Jan. 13, 2020

The New Jersey senator and former mayor of Newark formally tossed his name into the presidential hat on Feb. 1, the first day of Black History Month. Booker ran on a platform of ending mass incarceration if he were to be elected president. His absence in the race ahead of the caucuses made the remaining Democratic field significantly less diverse.

Marianne Williamson Democratic Party

Entered Race: Jan. 28, 2019

Dropped Out: Jan. 10, 2020

The "Healing the Soul of America" author and founder of Project Angel Food announced her candidacy during a political rally at the Saban Theater in Los Angeles on Jan. 28. Williamson ran on a platform of reparations and "economic justice for women and children."

Eric Swalwell

Entered Race: April 8, 2019 Dropped Out: July 8, 2019

The California congressman wrote in a statement on his campaign's website about his decision to bow out of the 2020 presidential race, "Ill never forget the people I met and lessons I learned while travelling [sic] around our great nation especially in the communities most affected by gun violence."

Seth Moulton Democratic Party

Entered Race: April 22, 2019

Dropped Out: August 23, 2019

The Massachusetts congressman and Iraq War veteran ended his campaign for president in a speech to the DNC in San Fransisco. I think its evident that this is now a three-way race between Biden, Warren and Sanders, and really its a debate about how far left the party should go, Mr. Moulton told the New York Times.

John Hickenlooper

Entered Race: March 4, 2019 Dropped Out: Aug. 15, 2019

The former Colorado governor supported stricter gun control laws and free trade.

Jay Inslee Democratic Party

Entered Race: March 1, 2019 Dropped Out: Aug. 21, 2019

The Governor of Washington ran on a platform focused on climate change, proposing a "100% Clean Energy for America Plan" that would see emissions drop to zero by 2035.

He announced he was dropping out of the race during an appearance on "The Rachel Maddow Show."

"It's become clear that I'm not going to be carrying the ball," Inslee told Maddow. "I'm not going to be the President, I'm withdrawing tonight from the race."

Inslee added that he's optimistic that climate change will be a major part of the Democratic party's priorities.

Kirsten Gillibrand - Democratic Party

Entered Race: Jan. 15, 2019

Dropped Out: Aug. 28, 2019

The senator from New York announced her bid Tuesday, Jan. 15 on "The Late Show With Stephen Colbert." Gillibrand, whose campaign slogan is "Brave Wins," supported paid family leave and protecting women's rights.

On August 28, 2019, she announced her withdrawal. "To our supporters: Thank you, from the bottom of my heart. Now, let's go beat Donald Trump and win back the Senate," she tweeted.

Howard Schultz Independent

Dropped Out: Sept. 6, 2019

In January the former Starbucks CEO expressed initial interest in running. In August, Schultz reportedly suspended his campaigning until after Labor Day, citing medical issues. In September, Schultz cited those issues and more in a letter on his website as reasons he had to take himself out of the running.

"My belief in the need to reform our two-party system has not wavered, but I have concluded that an independent campaign for the White House is not how I can best serve our country at this time," he wrote.

Schultz is a co-founder of the venture capital firm Maveron, which is an investor in TheWrap.

Bill De Blasio Democratic Party

Entered Race: May 16, 2019

Dropped Out: Sept. 20, 2019

The New York City mayor was looking for more taxes for the wealthy and regulating "gig jobs" under his proposed Universal Labor Standards.

Beto O'Rourke Democratic Party

See original here:
Watch Bill Mahers Campaign Ad for Democrats That Mocks Neurological Mess Trump (Video) - TheWrap

Posted January 27, 2020 15:24:40

The 2020 Australian of the Year, ophthalmologist James Muecke, plans to use his new title to increase awareness about the debilitating consequences of diabetes, but behind the scenes he has had to face his own health challenge.

The Adelaide eye doctor has spent about three decades working to prevent and treat blindness in some of the world's poorest countries.

"We're now seeing fantastic results. Children are surviving and they're actually keeping vision, which is immensely satisfying," Dr Muecke told 7.30.

"I loved the idea of doing very fine work with my hands and so microsurgery was always something that appealed to me as a doctor, and that then drove me down a pathway of ophthalmology.

"I loved the idea of surgery on the eye, such a delicate structure."

In a cruel twist, Dr Muecke has revealed he has been forced to stop doing the surgery he loves because of an inherited medical condition.

"Unfortunately I have a neurological disability which I've inherited from my father, which is impacting on my ability to use my right hand," he said.

"Fortunately it's not a life-threatening condition but it is a career-destroying condition.

"In the next year or two I'll have to bow out of my medical career sadly."

Having tackled some of the most confronting eye conditions, Dr Muecke is philosophical about his own medical challenge.

"I've met many people in my life who've had much tougher battles and their resilience is incredibly admirable," he said.

The condition has forced Dr Muecke to change his focus from surgery to advocacy.

He plans to use his Australian of the Year title to lobby hard for measures to tackle obesity, which can cause type 2 diabetes. The dietary-caused disease can cause blindness.

"Diabetes is now affecting one in 10 of our population," he said.

"Every year I'm seeing more and more patients who are losing vision as a result of this disease, a disease which is actually entirely preventable."

Dr Muecke is calling for a tax on sugar and said confronting advertising, similar to anti-smoking campaigns, was warranted.

"The government can help by reducing the time and space for sweet products, particularly during children's TV," he said.

"I think we need to have a clearer labelling system of sweet products, and for those products with high sugar content, taxing would be very important to help people choose lower sugar alternatives," he told 7.30.

Diabetes cost Neil Hansell his eyesight. He is now the face of Dr Muecke's campaign to highlight the debilitating consequences of the disease.

"Basically I went to bed one night, woke up the next morning and everything was black," Mr Hansell said.

"I would describe Dr Muecke as being very, very passionate at what he does, extremely loyal to all the people who come and see him.

"He's an inspiration really. I put him up there with Fred Hollows, he's that good."

It is an obvious comparison, but Dr Muecke said he was forging his own path.

"Well Fred [Hollows] was an absolute Aussie hero, he's a legendary character, he was an ophthalmologist like myself. Fred's passion was cataract blindness that is the leading cause of blindness in the world.

"My agenda is that there are quite literally hundreds of eye diseases, many of these are blinding and some are deadly," he told 7.30.

Dr Muecke's charity work goes back decades. In 2000 he co-founded Vision Myanmar and a few years later Sight for All, an organisation which uses Australian and New Zealand eye specialists to train overseas doctors.

"We've trained colleagues across many of the poorest countries in Asia, including Cambodia, Laos and Myanmar, and ultimately our projects are now impacting on roughly a million people every year," he said.

Watch this story on 7.30 tonight.

Topics:doctors-and-medical-professionals,health,eyes,diseases-and-disorders,diabetes,australia,adelaide-5000,sa

Go here to see the original:
Australian of the Year James Muecke forced to give up surgery due to neurological condition - ABC News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Immunitas Therapeutics (Immunitas), an innovative single cell genomics discovery platform company focused on developing breakthrough immuno-oncology therapies, today announced it has appointed Jeffrey M. Goldberg as Chief Executive Officer and Director. He succeeds founding CEO, Christoph Westphal, M.D, Ph.D., who assumes the role of Chairman of the Board of Directors.

One of the central challenges of drug development has been bridging the gap between laboratory research in model organisms to meaningful clinical advances in humans, said Jeff Goldberg. Immunitas and our scientific co-founders use single cell genomic sequencing and sophisticated computational biology techniques to look at human biology directly. I believe this innovative approach can help to accelerate the development of new therapies for patients. I am excited to be joining the Immunitas team as we discover and develop these highly targeted new immuno-oncology therapies.

Immunitas identifies novel, promising oncology targets with potential applicability across both solid and liquid tumors. Additionally, as part of the discovery process, Immunitas develops key biomarkers to guide the selection of patients who may benefit from its new drugs. The company leverages its expertise in antibody discovery and engineering to create therapies that modulate these targets. Immunitas is currently advancing a number of programs toward early human studies, including a lead program with fully-human monoclonal antibodies that will be developed as single agents using a clinical biomarker strategy to guide early efficacy studies.

Jeff Goldberg has over 20 years of industry experience driving programs from discovery through all phases of drug development to commercialization in multiple therapeutic areas, including oncology, neurology, renal, and rare diseases, said Lea Hachigian, President and Director, Immunitas Therapeutics. We are fortunate to have his demonstrated ability leading and building teams as we create an oncology company powered by our human biology-focused approach to immunology.

Mr. Goldberg joins the Immunitas Board of Directors, which includes Dr. Laura Brass, Managing Director at Novartis Venture Fund, Dr. Jrgen Eckhardt, Head of Leaps by Bayer, Bayers strategic venture capital unit, Dr. Lea Hachigian, Principal, Longwood Fund, Dr. Lucio Iannone, Director of Venture Investments of Leaps by Bayer, Dr. Christoph Westphal, co-founder and General Partner of Longwood Fund, and Dr. Vincent Xiang, Managing Director at Hillhouse Capital.

Jeff Goldberg is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre-clinical through IND, clinical trials, NDA, and commercialization in multiple therapeutic areas, including oncology, neurology, renal, and other rare and orphan diseases. Mr. Goldberg joins Immunitas from Akcea Therapeutics, where he was Chief Operating Officer from the time of its formation in January 2015. Previously, Mr. Goldberg was VP of Business Operations, leading both program management and business development at Proteostasis Therapeutics, Inc., a biotech company focusing on neurology and rare diseases. He also spent more than 11 years in positions of increasing responsibility with Genzyme and Sanofi, providing brand management for two marketed products within Sanofi Oncology. Prior to joining Sanofi Oncology, Mr. Goldberg served as Global Program Lead for Genzyme's stem cell mobilization agent Mozobil, leading the global launch team and overseeing the program management and marketing functions for the product. He began his career at Genzyme as Director, Program Management overseeing the development and launch of Renvela in patients undergoing dialysis. Mr. Goldberg has both an MBA and a Master's degree in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.

About Immunitas Therapeutics

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs. Lead programs from this platform have demonstrated single agent activity against challenging tumors and fully-human monoclonal antibodies are advancing towards clinical studies. http://www.ImmunitasTx.com.

Immunitas the human approach to oncology

Read the rest here:
Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics - Business Wire

Thom, who has a terrific stage voice and manner, leaves no question as to the theaters loss in limiting her range of roles. Her performance of Mouth is as terrifying as any and yet, in its vulnerability to neurological static, more human than most. You understand how the very lonely woman Beckett wrote could have wound up that way.

I would hate to have missed this performance, and yet it might easily never have happened. Feeling for too many years that theater was not a space I could occupy, Thom said in a post-show discussion, she almost gave up on it. (As a performer, she would have been deemed uncastable; as an audience member, disruptive.) Only in finding Not I, produced by Battersea Arts Center along with Thoms organization Touretteshero, did she find a way to occupy the only seat in the house I couldnt be asked to leave.

Thats admirable, sure. But the key is that once seated there, Thom uses her position to explore something beyond just Tourettes. Shining a light into Beckett from a different angle, she illuminates a different part of the rest of us as well.

A similar idea animates The Shadow Whose Prey the Hunter Becomes, running at the Publics Manhattan mother ship through Jan. 19. At first, the play seems to be merely a witty piece of documentary theater, recreating a real-life meeting at which the performers (Michael Chan, Simon Laherty, Sarah Mainwaring and Scott Price) bicker over their parliamentary roles and chafe about definitions. Some, we learn, are comfortable calling themselves disabled but others are not; Price thinks of himself as someone who, in addition to a thick Australian accent, has an autistic dialect.

The equating of accent and autism, one of which we usually consider trivial and the other hugely portentous, was eye-opening for me. If Prices autism is a dialect, surely my own neurological makeup is one, too. What are all our habits of thinking, our charming neuroses, our nature and character, if seen uncharitably, but undiagnosed defects? What is so typical about neurotypical minds?

Excerpt from:
When Disability Isnt a Special Need but a Special Skill - The New York Times

In the modern world, with seemingly simple conveniences such as refrigeration and electricity, perspective is hard. Understanding how to preserve foodeven knowing what actually qualified as foodrequired a lot of trial and error for our first 350,000 years on this planet. What we call progress isn't always the case. For every advancement there is a cost.

Obesity would have been a hard concept for our ancestors to understand. There was little opportunity for it to emerge. Advancements in food preservation and storage, such as processed foods and ice boxes, opened up an entirely new means of existence. We've paid for those technologies with "diseases of affluence," such as cardiovascular disease and type 2 diabetes. Humans were not biologically designed to have food, especially high-calorie food, perpetually available.

Authors of a recent study funded by The National Institute of General Medical Sciences and University of Virginia Brain Institute and published in Current Biology write that, "The widespread availability of energy-dense, rewarding foods is correlated with the increased incidence of obesity across the globe." The team, led by University of Virginia biology professor Ali Gler, discovered a link between the brain's biological clock and pleasure centera link that is driving obesity.

The obesity problem is the result of a perfect storm. Humans were designed to gorge when food is available; previously, we didn't know when the next meal would arrive. That's no longer the case. High-calorie foods, those crammed with sugars and carbohydrates, activate our brain's pleasure center; the good feeling is a biological signal for satiation. We feel satisfied then become addicted to and dependent on that feeling. Processed food companies have long exploited this fact. The ability to store food for extended periods of time, a relatively new capability, ensured that our next mealour next fifty mealsare waiting in the kitchen.

Electricity prompted not only the emergence of refrigeration, but also indoor lighting and eventually smartphones, which also play a role in this conundrum. The sun, for most of time, served as a natural alarm clock. We rose and set with it. As this is no longer the case, we thwart our biological rhythm by sleeping at odd hours or not enough, both of which negatively impact our health. The constant usage of phones also negatively impacts our circadian rhythm, with poor sleep also contributing to the obesity epidemic.

Whereas high-calorie foods were previously difficult to secure, Gler says that this is no longer the case.

"The calories of a full meal may now be packed into a small volume, such as a brownie or a super-size soda. It is very easy for people to over-consume calories and gain excessive weight, often resulting in obesity and a lifetime of related health problems."

Readily available high-calorie foods set off our pleasure center, causing us not only to overeat at meal time, but to snack all day. This is one of the surest ways to gain weight, the study notes. Tragically, our bodies store more calories eaten between meals as fat than those eaten during regular meal times.

"We're learning that when we eat is just as important as how much we eat. A calorie is not just a calorie. Calories consumed between meals or at odd hours become stored as fat, and that is the recipe for poor health."

Not actually food.

Photo by: Jeffrey Greenberg/Universal Images Group via Getty Images

Obesity is costing the United States $147 billion every year. Even the richest nation on Earth cannot afford this bill, especially given how much better we can utilize that money.

One important way that we can combat this trend is by closing our feeding window. As research has shown, Americans eat in an average feeding window of 14.75 hours a day. Intermittent fasting has been shown to help promote weight loss. While there are debates regarding exact fasting duration, it appears that closing your feeing window to a 10-hour period is beneficial. Some research has even even suggested that a 12-hour feeding window is helpful for shedding pounds.

Gler notes that "we evolved under pressures we no longer have." Our pressures are different now, such as this exploitation of our innate pleasure-seeking capacities. Convenience always comes at a cost. Refrigerators and light bulbs have not been everyday objects for that long of a time, and while we don't have to envision living without them, we can certainly make better use of both.

Line up the timeline of obesity trends with technological advancements and we are on safe ground speculating beyond correlation. As this study shows, it's part of our genetic inheritance: give us food and we'll eat it. Closing your feeding window and eating fewer carbohydrates might fly in the face of common wisdom, but nothing is wise about the situation we're in. Good health demands of us this discipline.

--

Stay in touch with Derek on Twitter and Facebook. His next book is Hero's Dose: The Case For Psychedelics in Ritual and Therapy.

From Your Site Articles

Related Articles Around the Web

Read the original post:
A new study shows the neurological reason for obesity and how to combat it - Big Think

Welcome tothe University Neurology Cole Neuroscience Center. We are a full-service neurology clinic, offering neurological consultation, Nerve Conduction Studies (electrical testing of nerve function), EMG (a test of muscle and nerve function), and EEG (brainwave testing).

Our Center was established as a result of the generous support of Robert and Monica Cole and the ColeFamily Foundation. The Cole Family Foundation made a strong commitment not only to clinical care, but also to research in the field of neuroscience. Through solid leadership and financial support of the Cole Family Foundationthe commitment to clinical excellence is evidenced by the growth in the patient population from a few hundred fifteen years ago to over 5,000 patients. Scientific research started with Cole Familys participation as the major benefactor in the acquisition of the first PET scan at TheUniversity of Tennessee Medical Center and the endowment of a chair in Molecular Neuro Imaging.

Our specialists work together to develop treatment plans that assist the entire family. From access to the latest diagnostic tools and the newest clinical trials, to offering counseling and long-term care options, the University Neurology Cole Neuroscience Center has so much to offer especially hope.

Conditionstreated in our office include:

Wetake a multidisciplinary approach to patient care. This effort is coordinated by our neurologistsas well as advanced registered nurse practitioners, social workers, registered nurses and a team of cognitive evaluation specialists.

Spanning beyond traditional approaches, the primary medical team also consults with neuroradiologists, neurosurgeons, nutritionists, and physical, occupational, respiratory, and speech therapists. The result of this collaboration is a unique program of care developed with each patient and their caregiver that addresses all their specific needs.

Download new patient packets and get general patient information. Learn More

More here:
University Neurology Cole Neuroscience Center - UTMC

New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Pacemakers Market to 2027 - Regional Analysis and Forecasts By Product Type By Technology, By End User, and Country" - https://www.reportlinker.com/p05806319/?utm_source=GNW

The electronic medical implant is an emerging field in the medical industry and has led to various developments of the products, in the field of cardiology, neurology, and otology.Many of the market players are developing novel products in order to minimize the burden of cardiovascular diseases, neurological disorders, and hearing disorders.

For instance, in November 2017, Medtronic launched Azure pacemakers with BlueSync technology that increases the life of the pacemakers, thus reducing the number of device replacements.It also enables to secure and automatic wireless data transmission to physicians.

Similarly, in July 2016, BIOTRONIK headquartered in Germany received CE approval for its new Edora pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps). Moreover, the presence of pacemaker manufacturers in the European region is also likely to influence the pacemaker market in the European region. Osypka Medical GmbH, Cardiac Impulse S.R.L., Sorin Biomedica C.R.M., S.R.L. are manufacturers located in Europe.In 2018, Europe pacemaker market held a market share of 22.8% of the global pacemaker market. The implantable pacemakers segment expected to dominate its market share and was valued at US$ 855.5 Mn in 2018 and is anticipated to reach US$ 1,687.2 Mn by 2027. On the other hand, implantable pacemakers segment is also anticipated to witness the fastest growth rate of 8.0% during the forecast period, 2019 to 2027.Similarly, in 2018 single-chambered pacemaker segment by technology was valued at US$ 890.2 Mn in 2018 and is anticipated to reach US$ 1,736.8 Mn by 2027 and is also expected to grow at the fastest growth rate of 7.9% during the forecast period.Furthermore, the hospitals & clinics segment held the largest market share of is also anticipated to witness the fastest growth rate of 8.0% during the forecast period, 2019 to 2027. This segment is also expected to dominate the market in 2027 as it is the primary care center for most of the population.Some of the major primary and secondary sources for endodontic devices included in the report are, European Commission, European Society of Cardiology, World Health Organization, European Patent Office, International Trade Administration (ITA) among others.Read the full report: https://www.reportlinker.com/p05806319/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original post:
The Europe pacemaker market is expected to reach US$ 2,408.5 Mn in 2027 from US$ 1,248.7 Mn in 2018 - GlobeNewswire

Neurological disorders are diseases of the brain, spine and the nerves that connect them. There are more than 600 diseases of the nervous system, such as brain tumors, epilepsy, Parkinson's disease and stroke as well as less familiar ones such as frontotemporal dementia.

UCSF Medical Center is one of the top hospitals in the nation in neurology and neurosurgery, according to U.S. News & World Report. We treat conditions from the common to rare and draw on our research to provide the most advanced therapies available.

We have one of the largest brain tumor treatment programs in the United States and one of California's largest cerebrovascular surgery programs. Our advanced treatments include Gamma Knife radiosurgery, which delivers a finely focused, high dose of radiation precisely to its target. It is used to treat small to medium size tumors, epilepsy, trigeminal neuralgia and abnormal blood vessel formations deep in the brain.

In Northern California, we have the only comprehensive memory disorders center and the largest center for the treatment of Parkinson's disease. We also have leading experts in the treatment of peripheral nerve disorders such as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), a progressive degeneration of nerve cells controlling muscle movements.

Neurological support groups for patients and their families are open to the public.

The rest is here:
Neurological Disorders | Conditions and Treatments | UCSF ...

Welcome to Boston Children's Hospital's Department of Neurology! We care for infants, children and adolescents with all types of neurologic and developmental disorders. From diagnosis through long-term follow up, we provide compassionate, comprehensive support to help every child reach his or her full potential. Science informs our care today and our work toward better care tomorrow.

Were proud to uphold a historical legacy that dates to 1929, when we became the first dedicated child neurology service at a U.S. pediatric hospital. We went on to establish the countrys first pediatric epilepsy unit (in 1944), the first comprehensive pediatric sleep center (in 1978) and the first dedicated pediatric neurocritical care program (in 1996).

Neurology programs and services: Our neurologists care for children with epilepsy, cerebral palsy, birth defects, muscular dystrophies and other neuromuscular disorders, brain injury and concussion, neurodevelopmental disorders including autism, sleep problems, headache, multiple sclerosis and neuroinflammatory disorders, movement disorders, brain and spinal tumors, cerebrovascular disorders, metabolic disorders and more.

Patient and family resources: How to access our services, preparing for your appointment, care in the community, our patients stories and more.

Boston Childrens Hospital Neurology in the news

7 questions parents should ask in seeking neurologic care: A list of questions to ask when comparing different centers and programs.

U.S. News & World Report has ranked Boston Childrens Hospital as having the nations #1 Neurology/Neurosurgery program. Here are a few reasons:

Comprehensive services: Through nearly 40 specialized programs, we treat more nervous system conditions than any pediatric neurology program in the world, including rare and complex disorders. We offer advanced clinical services including a rapid response team, specialized Level 4 epilepsy care, genetics, rehabilitation programs and biofeedback treatment for headache.

Superior medical capabilities: With more than 60 child neurologists, 10 neuropsychologists and psychologists and 30 nurses and nurse practitioners, we offer highly specialized, individualized care. We have received high marks for medical best practices in neurology and neurosurgery and for use of the most advanced technologies, and have been accredited for high nursing standards by the American Nurses Credentialing Center.

Quality orientation: We collaborate with multiple specialists to ensure the best possible care. All childrens outcomes are tracked in a quality control database. We also share data with the Pediatric Neurocritical Care Research Group and the National Healthcare Safety Network to continually improve care.

Supportive, holistic care: Our broad-based team provides family-centered care to meet each childs medical, emotional and educational needs. A family resource center, family support specialists, pediatric psychologists, social workers and a parent advisory committee are available to you and your child. We also house the hospitals Bullying & Cyberbullying Prevention & Advocacy Collaborative (BACPAC).

Science and innovation: At any given time, our child neurologists are engaged in dozens of clinical trials to test new treatments. Our F.M. Kirby Neurobiology Center is the nations top neuroscience hub with more than two dozen laboratories driving tomorrows treatments. Our doctors and scientists work together to bring advances into patient care.

Read more here:
Neurology | Boston Children's Hospital

The Pediatric Neurology Division at University Hospitals Rainbow Babies & Childrens Hospital is one of the most active service, training and research programs in the upper Midwest of the United States, and is devoted to the diagnosis and care of children with neurological problems.

Since 1997, the Neurology Division at UH Rainbow Babies & Childrens Hospital has expanded to include eight pediatric neurology faculties, two advanced practice nurses and two RNs to provide both outpatient and inpatient consultations for children and their families. Our team provides family-centered care for the full range of neurological challenges to the child and his or her family.

Pediatric neurology faculty are certified by the American Boards of Neurology and Pediatrics. Each physician brings to our Division expertise in specific areas of epilepsy, metabolic-genetic disease, sleep medicine, headaches, neuro-oncology, behavioral and cognitive neurology (including ADHD, Tourettes syndrome and Autism), and the care of multiple-handicapped children including those with cerebral palsy.

Multiple programs are embedded into the Rainbow Neurological Center which is part of the Neurological Institute at University Hospitals Cleveland Medical Center. Integrated service, educational and research programs provide care for children with epilepsy, developmental delay, headaches, brain tumors, stroke, movement disorders, cognitive and behavioral disorders, and neurointensive care and fetal neurology needs.

Continued here:
Division of Pediatric Neurology | University Hospitals ...

An understanding of the pathologic basis of neurologic diseases is essential for understanding both the clinical manifestations of the disease, as well as the potential treatment paradigms.

The focus of the neuropathology rotation is diagnostic aspects of neuropathology including surgical neuropathology , autopsy neuropathology, and neuromuscular pathology. In particular, clinical-pathologic correlations will be stressed. The resident will attend and participate in the weekly neurology/radiology/neurosurgery conference( Friday 9-10am).

In this one month elective, the resident will gain familiarity with both common and rare neuropathologic diseases, develop a solid foundation in morphologic diagnosis, and acquire an in depth understanding of the utility of ancillary techniques such as immunohistochemistry, molecular diagnostics, and electron microscopy.

The program is structured to meet this goal through exposure of the resident to an abundance of diversified case material, a commitment to medical teaching, state-of-the-art clinical laboratory facilities, and a graduated program of assigned responsibilities.

At the end of this rotation the resident should be able to identify normal and pathologic gross and microscopic anatomy, identify the findings in major neuropathologic diseases, and generate appropriate differential diagnoses based upon neuropathologic findings.A pretest will be given at the beginning of the rotation and a post test will be taken at the end of the rotation to document the progress made by the resident during the rotation.

Suggested Reading:

Brain cutting at TUH morgue: Tuesdays 9-10 amCases from the previous weeks are discussed and examined at the gross level focusing on both autopsy neuropathology concepts as well as general neuroanatomy.Autopsy confererences at Multiheaded scope: Tuesdays 8-9 amInteresting findings from the autopsy brains are presented to the residentsMonthly neuropathology lecture/ slide conference: The didactic session cover topics such as CNS infectious diseases, neurodegenerative diseases, and trauma; while the unknown case conferences focus on CNS tumor pathology. For the later, residents are given a series of 5-6 cases with clinical history for review prior to the conference, and asked to formulate a working differential diagnosis for each of the cases.

Read the original here:
Neuropathology | Lewis Katz School of Medicine

When you need expert care for diseases affecting your brain, spinal cord or nervous system, the neurologists at University of Missouri Health Care provide the most advanced care in central Missouri.

We offer the widest range of options and the most advanced medical capabilities for neurological disorders in the region, including specialized care for kids.

Neurological diseases involve different parts of the nervous system, so our neurologycare team includes specialists in brain and spinal cordillness, muscle and joint conditions and other medical specialties. We create your care team based on your unique needs.

As an academic health center, MU Health Care has experts in every medical specialty. Thats important for you because it means you can get all your care in a single place. Regardless of your condition, we have the expertise and resources to offer you complete care.

Our neurologists are also researchers and educators, so your care team is knowledgeable about the latest therapies. If theres a promising new treatment, youll find it at MU Health Care including treatments only available through clinical trials. Our doctors are on the forefront of the latest discoveries in neurological disease research.

Neurologicaldiseases require complex care from a number of specialists, so we make your care as convenient as possible. Your care team may include doctors, nurses, dietitians, pharmacists, respiratory and rehabilitation therapists, orthotists (clinicians who specialize in limb and spine braces or prostheses) and other clinicians.

We treat many types of neurological diseases, including:

Your neurologist will design a care plan that helps you maintain as much independence and function as possible. We draw from a variety of services to help improve your quality of life and support you and your family, including:

At MU Health Care, youll receive a full spectrum of personalized neurological care and services.

Read the original post:
Neurology - MU Health Care - Columbia, MO

Advanced Care for the Brain and Nervous System

Neurology is the branch of medicine that deals with the anatomy, functions, and disorders of the brain, nerves and the nervous system. Neurologists evaluate patients to determine the causes of pain, seizures, confusion and other neurological conditions.

Our neurologists are board certified to evaluate and treat general neurological concerns in addition to specialized conditions like Parkinsons disease, myasthenia gravis, epilepsy and migraines.

Virtua has partnered with Penn Medicine to bring the regions foremost leader in neurological treatment and research to South Jersey. The Penn Medicine Virtua Neurosciences Alliance is another way these two great health systems are working together to ensure the highest level of care is available to Virtua patients and all South Jersey residents.

Stroke is the sudden death of brain cells due to lack of oxygen. It's caused by blockage of blood flow or rupture of an artery to the brain. Sudden loss of speech, weakness, and paralysis on one side of the body are dramatic symptoms of stroke.

When symptoms appear but quickly fade away on their own, it's called a transient ischemic attack or mini-stroke, which is often a precursor to a stroke. Strokes can be diffuse (affecting multiple areas of the brain a little) or focused (affecting one part of the brain a lot). Virtua neurologists are experts in determining the causes of stroke, managing side effects and rehabilitation, and minimizing the risks of having another.

Virtua is investing in new technology to provide long-term epilepsy monitoring at all of its inpatient campuses. Virtua neurologists will be able to continuously monitor seizure activity to fine tune treatments and medication to minimize seizures and side effects.

Penn Medicine offers additional, advanced diagnostics and therapeutic interventions. Specialists at the Penn Epilepsy Center provide comprehensive evaluation and treatment for patients with epilepsy, seizure disorders and all seizure-associated symptoms including memory and mood problems. The program is led by experienced Penn neurologists who are recognized leaders in the research, diagnosis, and medical and surgical treatments for epilepsy.

The Penn Epilepsy Center is recognized by the National Association of Epilepsy Centers (NAEC) as a Level 4 epilepsy center. Level 4 epilepsy centers have the professional expertise and facilities to provide the highest-level medical and surgical evaluation and treatment for patients with complex epilepsy.

Read the original here:
Neurology & Neurologist Services in Southern New Jersey

Learn more about UH Neurological Institutes General Neurology Center

University Hospitals Neurological Institutes Community Neurology Center provides expert testing, diagnosis and treatment for diseases of the nervous system at convenient locations throughout the community.

As a University Hospitals Center of Excellence, the center brings together leading experts across many different areas of specialty. They work together and use the latest clinical advances and technologies to benefit patients. In fact, many are involved in nationally funded research and are continuously working to discover future innovations.

The Community Neurology Center is the best starting point for new patients with undiagnosed neurological disorders and those seeking second opinions. Depending on the diagnosis, patients may be referred to one of the specialized centers within UH Neurological Institute, or receive treatment through our community neurology programs.

UH Neurological Institute integrates its wide range of capabilities with our community-based hospitals and medical centers to ensure that patients receive the same high level of innovative, personalized care regardless of location.

Our team of physicians and other specialists has over 60 years of combined experience in diagnosing and treating a full range of neurological disorders. They work closely with UH Neurological Institute specialists experienced in:

Continued here:
Community Neurology Center | University Hospitals ...

A few years ago, I was shadowing a neurologist at a hospital just down the road from my family home in Connecticut. It was a relatively slow day for the doctor, full of chart reviews and sifting through brain images for abnormalities. As she went about her paperwork, the neurologist shared her insights with me, especially when something exciting popped up. Even then, I remember finding it strange that the human body can be a medical educatorsomething to be studied, even marveled at.

I learned what an ischemic stroke looked like on a CT scan. I saw what electronic health records looked like across an assortment of patients and their health statuses, annotated by past and present health care providers. I read what doctors considered to be objective truths about their patients, truths including data points and test results that were worthy of being documented. I read the things that mattered to insurance companies and provided the doctors their paychecks. I saw a complicated system of documentation that put the medical record and physician reimbursement at the heart of patient-centered health care.

And I read snippets of patients subjective realities of their ailments that the chart authors annotated with phrases like patient insists [x] or patient seems convinced of [y] or even patient comes in frequently, seeking attention. It was as if the narrative of a persons own lived experience was not trustworthy enough for science, or at least not relevant enough to be taken seriously within our fee-for-service model of health care. There was no way a patient could be the first author in their own story, a coveted role reserved for the educated, the objectivethe clinicians.

In the medical field, we often talk about the fine balance between personal responsibility and social determinism in influencing health behaviors. But when patients with real concerns and conditions take their health into their own hands, they are judged, and labeled attention-seekers, when science has no answers for them. Maybe its because objective data is comforting to analytic, medical minds. But when no data exist to explain particular illnesses and when time is money, it becomes easier to view the body in front of you as one of a hypochondriacal, noncompliant or attention-seeking person than to truly listen and strengthen the bond of a doctor-patient relationship. Unfortunately, this attitude doesnt make for good medical care because somehow, while looking through even the most mundane of reading materials that daya patient chart riddled in complicated medical jargon and some abbreviations that I still have to google as a medical studentI could almost hear the chat's author scoff in judgement.

With the rise of electronic health records and ever-improving technology, one might be inclined to believe that these changes bring more benefit than harm to health care. While on the surface this might seem true, like everything else in our world, its not that simple. It means patients get significantly less time with doctors and feel more neglected than ever. It means people are living longer but with more chronic conditions. It means patient-centered care is being swapped for patient-centered charts. It means care providers are less focused on patients and more concerned with the bottom line.

As a result, they are suffering from more burnout than ever before. In fact, a 2018 survey by the Physicians Foundation found that six out of every 10 doctors surveyed (9,000 total) were either very or somewhat pessimistic about the future of the medical profession, citing electronic health record design and the patient-physician relationship for their marked dissatisfaction. In large part, this pervasive issue owes itself to shifts in medical culture from house calls and bedside manner in the early 1900s to 15-minute check-ins and a focus on profit margins in 2020.

Fortunately, however, not all health care professionals treat their patients and their bodies as medical specimens. Some physicians, like the neurologist I was shadowing, take the time to know their patientsand their familiesbeyond medical charts and insurance documentation. Because it can be difficult to mentally construct patients lives and narratives from the medical lingo of their charts, the doctor filled in the gaps for me that day. She gave life and meaning to abridged notes and otherwise apathetic paperwork. She told me about a young man who was likely taking his last breaths following a combined alcohol/cocaine/narcotics overdose.

While I was there, she was called to the ICU to examine him for the nth time in as many days. On the elevator ride up, she told me he was a college student who had been doing careless college student things. Her motherly disappointment was laced with a hint of sadness. I figured cases like these were commonplace for her, but it was humbling to see her humanness, especially since I didnt know what I was walking into that day. I wondered what it meant to be an overdose patient in a culture that was full of overmedicating, over-testing and over-charting, none of which offered an iota of humanity to a patient on the verge of death or a family nearing an irreplaceable loss.

She led me to her patients room in the ICU. He was no more than a year or two older than I was at the time. As I watched the ventilators help his limp body inhale and then exhale, I imagined he might have had a bright future ahead of him. I thought about the college party that allegedly landed him in this place. I wondered if he had been addicted or couldve been helped. I wondered who he would be leaving behind. I said a silent prayer for him as the doctor examined him, once again confirming a poor prognosis.

Quick footsteps approached. The doctor stepped into the hall to greet her patients mother. It became clear that his mother was just as much in need of the doctors warmth and care as he was. And because the neurologist was what I considered to be a good doctor, maybe even a rare one, she recognized it too. I listened as the doctor relayed a difficult prognosis. I watched the mother clutch her prayer beads so tightly her knuckles turned white. I learned that her son attended an Ivy League university and would be leaving behind a seemingly supportive and, at the moment, extremely distraught family. I know hell be okay she argued. She had seen him move. I remembered learning that overdose-related comas can result in elevated levels of motor activity due to the drugs effects on the brain stem. Contrary to what a hopeful mother might believe, this was not a reflection of consciousness or active motor reflexes.

The doctor, though she spoke matter-of-factly, delivered her professional opinion with patience and kindness. She was present for the mother. She understood that the lifeless young man in front of her was not just a body or another looming overdose death. He was someone with a family, a life that was worth living. She also saw a grieving mother before her who would soon have to make peace with this tragedy. Observing their interaction, I could see that most of the medical information the doctor shared flew past the womans ears. She was a mother, and she knew what she had seen; she fully believed that her son was on the cusp of waking up again. As a physician, the neurologist knew he wasnt going to get better; the damage was too far gone.

That day, I saw that ultimately it is not the language of science or evidence-based medicine that consoles real human beings facing real loss. It is not the objective medical gaze or microscopic view of the body as a specimen that provides comfort or reassurance. It is not the contrived form of empathy we are taught to show our patient-actors in our clinical skills courses that builds trust between doctors and their real patients. A scripted Oh, Im sorry to hear that. That must be so tough for you, only goes so far when youre caring for the sick and dying and their family members. In the end, the reality of medical practice and the doctor-patient relationship is about the impulse of being human, the vulnerability of being ill, and the process of healing, all of which we share in but so often forget in the process of becoming professionals.

But in this instance with the neurologist, I saw what it meant to look beyond a patients chart and to deviate from the feigned sympathy script of a medical school doctoring course. I saw a young man as a patient, a person with his own story; a mother in sorrow, no less a patient in that moment; and a doctor with oodles of knowledge standing quietly in solidarity with her patients mother. The neurologist reached her hand out and the mother graciously accepted her show of comfort, genuine and uncontrived. That, to me, is patient-centered care. Id be curious to see how a medical school might script that or how an electronic health record or insurance company might capture it for reimbursement.

Read the original:
What Does It Mean to Be a Good Doctor? - Scientific American

Inland Neurology offers compassionate care for you and your loved ones. It is our goal to provide considerate, attentive care for the individual health needs of every patient. We believe in educating our patients with the best information we have, so that you can make the decisions that works best for you and your family.

Inland Neurology is a department of Inland Hospital. The practice is located at 246 Kennedy Memorial Drive, Suite 102, Waterville, Maine. Phone: (207) 861-7050. Inland is a proud member of EMHS.

Healthcare Services:Evaluation and treatment of neurological conditions including:

Office Hours:

Monday - 7:30 a.m. - 4:30 p.m.Tuesday - 7:30 a.m. - 4:30 p.m.Wednesday - 7:30 a.m. - 4:30 p.m.Thursday - 7:30 a.m. - 4:30 p.m.Friday - 7:30 a.m. - 4:30 p.m.

Appointments:Patients are seen by appointment with flexibility in our schedule to handle urgent medical cases.

In-House Services:

Financial Policies:

Here is the original post:
neurology services maine, stroke recovery maine, stroke ...

Global Oncology & Neurology Disorder Drugs Market 2019 by key players, regions, type, and application, forecast to 2026. Oncology & Neurology Disorder Drugs Market Report contains a forecast of 2019 and ending 2026 with a host of metrics like supply-demand ratio, Oncology & Neurology Disorder Drugs Market frequency, dominant players of Oncology & Neurology Disorder Drugs Market, driving factors, restraints, and challenges. The report also contains market revenue, sales, Oncology & Neurology Disorder Drugs production and manufacturing cost that could help you get a better view of the market. The report focuses on the key global Oncology & Neurology Disorder Drugs manufacturers, to define, describe and analyze the sales volume, value, market competition landscape, market share, SWOT analysis and development plans in future years.

Download Free Sample Copy of Oncology & Neurology Disorder Drugs Market Report: https://dataintelo.com/request-sample/?reportId=44608

The report provides information on trends and developments and focuses on market capacities, technologies, and the changing structure of the Oncology & Neurology Disorder Drugs Market . The new entrants in the Oncology & Neurology Disorder Drugs Market are finding it hard to compete with the international dealer based on quality and reliability.

Major Players included in this report are as follows ProStrakanPacira PharmaceuticalsAbbottGlaxoSmithKlineTranscept PharmaceuticalsArchimedes

Oncology & Neurology Disorder Drugs Market can be segmented into Product Types as Product Type IProduct Type IIProduct Type III

Oncology & Neurology Disorder Drugs Market can be segmented into Applications as Application IApplication IIApplication III

Oncology & Neurology Disorder Drugs Market: Regional analysis includes: Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Buy the full version of this report at: https://dataintelo.com/checkout/?reportId=44608

Influence of the Oncology & Neurology Disorder Drugs Market report: Comprehensive assessment of all opportunities and risk in the Oncology & Neurology Disorder Drugs Market. The Oncology & Neurology Disorder Drugs Market recent innovations and major events. A detailed study of business strategies for growth of the Oncology & Neurology Disorder Drugs Market-leading players. Conclusive study about the growth plot of Oncology & Neurology Disorder Drugs Market for forthcoming years. In-depth understanding of Oncology & Neurology Disorder Drugs Market-particular drivers, constraints and major micro markets. Favourable impression inside vital technological and market latest trends striking the Oncology & Neurology Disorder Drugs Market.

Objective of Studies: 1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Oncology & Neurology Disorder Drugs Market. 2. To provide insights about factors affecting the market growth. To analyse the Oncology & Neurology Disorder Drugs Market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc. 3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World. 4. To provide country level analysis of the market with respect to the current market size and future prospective. 5. To provide country level analysis of the market for segment by application, product type and sub-segments. 6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market. 7. To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Oncology & Neurology Disorder Drugs Market.

Customize Report and Inquiry for The Oncology & Neurology Disorder Drugs Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=44608

The huge assortment of tables, graphs, diagrams, and charts obtained in this market research report generates a strong niche for an in-depth analysis of the ongoing trends in the Oncology & Neurology Disorder Drugs Market. Further, the report revises the market share held by the key players and forecast their development in the upcoming years. The report also looks at the latest developments and advancement among the key players in the market such as mergers, partnerships, and achievements.

In short, the Global Oncology & Neurology Disorder Drugs Market report offers a one-stop solution to all the key players covering various aspects of the industry like growth statistics, development history, industry share, Oncology & Neurology Disorder Drugs Market presence, potential buyers, consumption forecast, data sources, and beneficial conclusion.

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataIntelo Name Alex Mathews Email [emailprotected] Website https://dataintelo.com Address 500 East E Street, Ontario, CA 91764, United States.

See more here:
Oncology & Neurology Disorder Drugs Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 - News Times

Until recently, seriously ill people were often treated at home, surrounded by friends and family. As scientific advances have shifted medical care to the hospital, patients now rely on family visits for emotional support, and also for assisting with practical matters: helping with basic care, accessing old medical records, keeping track of medications. In my role as neurohospitalist at a county hospital, I have noticed another vital function of hospital visitors that is perhaps underappreciated: improving patient care.

I make daily hospital rounds with a neurology resident and occasionally medical students. Rounds are always hurried; we must examine every patient, review neuroimaging and laboratory results, discuss cases with consultants, and document everything in the cumbersome electronic medical record. We explain as much as we can to patients and their families.

However, many patients are alone with minimal, if any, ability to communicate. Often, neurology patients are encephalopathic or comatose, limiting our interaction. Some are homeless or have poorly controlled mental illness. The patient may be a "John Doe" whose true name is unknown. No visitors will arrive until administrators identify the patient. Demented elderly patients, many of whom have lost a lifelong partner, may also endure hospitalizations alone. In all these situations, without family to communicate with, my time in the room may be brief. Sometimes patients remain alone and incommunicado for days.

A concerned family also holds me to account.

The persistent absence of visitors seems to convey a silent message: "In the outside world, no one cares about me." Although visitors may not be in attendance for many reasonswork obligations, distance, lack of knowledge of the hospitalization, or even an independent patient's wishesan empty room advocates poorly for the patient.

Face-to-face time with each patient varies depending upon many factors, especially the complexity of the case and the clarity of the diagnosis. When family members are present, I take additional time to explain the diagnosis, prognosis, and therapeutic plan.

Sometimes that extra time improves the patient's care. It provides space for a more thorough exploration of the case and for consideration of fresh diagnostic and therapeutic options. Extra minutes may solidify a nascent therapeutic alliance. A concerned family also holds me to account, elevating the patient's importance in my mind.

Of course, longer patient visits aren't necessarily better visits. Families can be distracting when their needs and behavior pull focus from the patient.

But I often thank visitors for their presence and assistance. Many must sacrifice much needed income by taking leave from work, cope with unexpected travel expenses, or otherwise place their lives on hold. I have walked in those shoes and it is not easy.

Lately, after examining a patient alone in his or her room, I pause for a few seconds. I methodically wash my hands and thoroughly dry them with a paper towel. I scan the monitors. I watch the patient breathe. I let my thoughts settle.

Then I mentally explain the case to a nonexistent family member. Although patients cannot participate, they bear witness to these silent conversations. It's my hope that this additional attention improves their care. Maybe someday one of my patients will tell me.

Andrew Wilner is a professor of neurology at the University of Tennessee Health Science Center in Memphis, a health journalist, and an avid SCUBA diver. His latest book is The Locum Life: A Physician's Guide to Locum Tenens.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the original post:
How Family in the Room Affects Patient Care - Medscape

The report specifies the Global Minimally Invasive Neurology Device Market share held by the significant players of the business and conveys a full perspective on the focused scene. The market is ordered into various sections with the complete examination of each concerning the topography for the investigation time frame. The report has turned the spotlight on the startling rise in verifiable investigation and evaluations in the Minimally Invasive Neurology Device market with its future prospects.

This research focus on Top-down and Bottom-up research analysis progression, which will help investors to analyze the financial market and to perform desired operations to choose Minimally Invasive Neurology Device market investments in the forthcoming year 2020-2026.

Get a Sample copy of Minimally Invasive Neurology Device research report which will assist you to make better business decisions. [emailprotected] https://www.reportspedia.com/report/life-sciences/global-minimally-invasive-neurology-device-market-report-2019,-competitive-landscape,-trends-and-opportunities/28292 #request_sample

Key Players:

Mayo Clinic CompanySwedish Neuroscience Institute CompanyNICO Corporation CompanyXylos CorporationMedtronic plcTel Aviv Sourasky Medical Center CompanyHadassah Medical Center CompanyReplication Medical, Inc.StereoTools SAOptiscan Imaging Limited Company

Conformed by Reportspedia.com Research, the Minimally Invasive Neurology Device market has been predicted to expand at a growth rate during the forecasting years of 2020-2026, driven by various factors. For instance, the development of the market has been very crucial for the advancement of the Minimally Invasive Neurology Device market globally.

Minimally Invasive Neurology Device Market Competitive Analysis

The research report helps to identify business competitors and helps to evaluate their business strategies to define the key players strengths and weaknesses associated with the products and services offered by manufacturing industries. Competitive analysis is a critical process to identify Minimally Invasive Neurology Device competitors marketing plan, to attract your target market Reportspedia.com has provided analytical data, which contain graphs, charts, and business values to create unique product or services in the global market. It includes a brief analysis of Minimally Invasive Neurology Device industry competitors, competitors global and regional sell, competitors market share, past and current strategies, type of media to market product or services, and potential openings.

The Minimally Invasive Neurology Device Market has been categorized in the report :

Types:

Type 1Type 2Type 3

Applications:

Application 1Application 2Application 3

Want To Institute Strategies For Upcoming Years? Our Reports Can Assist You To Plot Superior. Inquire Here : https://www.reportspedia.com/report/life-sciences/global-minimally-invasive-neurology-device-market-report-2019,-competitive-landscape,-trends-and-opportunities/28292 #inquiry_before_buying

Regions:

South America Minimally Invasive Neurology Device Market Covers Colombia, Brazil and Argentina

North America Market Covers United States, Canada and Mexico

Europe Minimally Invasive Neurology Device Market Covers UK, Germany, Italy, France and Russia

The Middle East and Africa Market Covers Saudi Arabia, Egypt, South Africa, UAE and Nigeria

Asia Pacific Minimally Invasive Neurology Device Market Covers Korea, India, Japan, Southeast Asia and China

Key questions answered in this report:

Contents of the 12 Chapter for Global Minimally Invasive Neurology Device Market Study:

Section 1: Describe Minimally Invasive Neurology Device Market Introduction, detail scope, market review, market availabilities, market risk, market-main drive;

Section 2: To break down the best producers, with Sales, income, and cost of Market;

Section 3: To show the aggressive circumstance among the best producers, with Sales, income and Minimally Invasive Neurology Device market share in 2019;

Section 4: To demonstrate the Global market by regions, with sales, income, and offers for every area;

Section 5, 6, 7, 8 and 9: To break down the key districts, with Sales, income and Minimally Invasive Neurology Device market share by key nations in these areas;

Section 10 and 11: To demonstrate the Minimally Invasive Neurology Device market by type and application, with sales market suggestion and development rate by 2026;

Section 12: market conjecture, by locales, type, and application, with sales and income, from 2019 to 2026;

Ask for Detailed TOC of the Report. [emailprotected] : https://www.reportspedia.com/report/life-sciences/global-minimally-invasive-neurology-device-market-report-2019,-competitive-landscape,-trends-and-opportunities/28292 #table_of_contents

Finally, all the fragments have been dependent on present and future patterns and the Minimally Invasive Neurology Device market is assessed from 2020 to 2026.

Thanks a bunch for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. [emailprotected]

Read more here:
Global Minimally Invasive Neurology Device Market Demand Analysis, Development Factors, Overview with Manufacturers And Forecast 2026 - News Times